Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Amgen’s evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia... Learn More
Recorded live on October 22, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
This exciting one-day seminar provides attendees with a unique opportunity to hear in-depth analysis of hot topics and trends concerning global biosimilars while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
October 23, 2014
Abilify is the Most Commonly Prescribed Antipsychotic Drug Among Newly Diagnosed Bipolar Disorder Patients in the United States
Opposing Market Forces Lead to Limited Growth of the Acute Pain Market Through 2023
October 21, 2014
Biomarker-Driven Prescribing is Currently the Standard-of-Care for HER2-Positive Breast Cancer and EGFR-Mutation Positive NSCLC, According to Oncologists in Argentina and Mexico
October 20, 2014
The Age-Related Macular Degeneration Drug Market Will Grow to Nearly $9 Billion in 2023, Fueled in Part by the Anticipated Launch of the First Therapies for Geographic Atrophy
Physician Perspectives on Erythropoiesis-Stimulating Agents, Insulin, and Human Growth Hormone
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating... Read More
Prostate Cancer - 2014
Last Updated 24 October 2014The prostate cancer market has witnessed considerable changes over the... Read More
Oral HIF-PH Inhibitors for the Treatment of Renal Anemia in CKD Non-Dialysis and Dialysis: How Will U.S. Physicians and Payers Respond to This Novel Class?
Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney... Read More